Yahoo Search Busca da Web

  1. Anúncio

    relacionado a: metastatic colorectal cancer - epidemiology forecast - 2032 pdf

Resultado da Busca

  1. This Metastatic Colorectal Cancer (mCRC)- Epidemiology Forecast-2032 report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

  2. 27 de mai. de 2023 · Our current study forecasts that the heterogeneity of metastatic cancer will evolve, driven by significant alterations in the incidence of lung, colorectal, and breast cancers.

  3. 29 de abr. de 2022 · This Metastatic Colorectal Cancer (mCRC)- Epidemiology Forecast-2032 report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the...

  4. 20 de jan. de 2023 · Key points. For the best practice of metastatic colorectal cancer, the determination of tumour genomic status for KRAS and NRAS, BRAFV600E mutations, ERBB2, and microsatellite instability...

  5. 6 de jan. de 2019 · About 1,096,000 new cases of colon cancer are estimated to be diagnosed in 2018, while about 704,000 new cases of rectal cancer are expected. Together, these comprise 1.8 million new cases of CRC. CRC is the most diagnosed cancer among men in 10 of the 191 countries worldwide.

    • Prashanth Rawla, Tagore Sunkara, Adam Barsouk
    • 10.5114/pg.2018.81072
    • 2019
    • Prz Gastroenterol. 2019; 14(2): 89-103.
  6. 13 de fev. de 2023 · Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the ...

  7. 25 de out. de 2022 · Highlights. •. This ESMO Clinical Practice Guideline provides key recommendations for managing metastatic colorectal cancer. •. It covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. •. Treatment algorithms for locoregional, advanced/metastatic and recurrent advanced colorectal cancer are provided. •.